−1250KRW
−32.57 BKRW
18.86 BKRW
31.51 M
About CELLIVERY
Sector
Industry
CEO
Dae-Woong Cho
Website
Headquarters
Seoul
Employees (FY)
9
Founded
2014
ISIN
KR7268600004
FIGI
BBG00M147R68
Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmaceutical products. Its products include improved cell-permeable parkin (iCP-Parkin), cell/tissue permeable frataxin (CP-FXN), improved cell-permeable SOCS3 (iCP-SOCS3), cell-permeable BMP2 (CP-BMP2), cell-permeable truncated SOCS3 (CP-SD), improved cell-permeable nuclear import inhibitor (iCP-NI), and others. The company was founded by Dae-Woong Cho on March 14, 2014 and is headquartered in Seoul, South Korea.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 268600 is 6680 KRW — it has decreased by 29.91% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange CELLIVERY stocks are traded under the ticker 268600.
268600 stock is 42.66% volatile and has beta coefficient of 5.70. Check out the list of the most volatile stocks — is CELLIVERY there?
Yes, you can track CELLIVERY financials in yearly and quarterly reports right on TradingView.
268600 net income for the last quarter is −14.52 B KRW, while the quarter before that showed −3.91 B KRW of net income which accounts for −271.18% change. Track more CELLIVERY financial stats to get the full picture.
No, 268600 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 268600 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CELLIVERY stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 9.00 employees. See our rating of the largest employees — is CELLIVERY on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CELLIVERY technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CELLIVERY stock shows the strong sell signal. See more of CELLIVERY technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CELLIVERY EBITDA is −69.46 B KRW, and current EBITDA margin is −77.47%. See more stats in CELLIVERY financial statements.